Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the
peroxisome proliferator-activated receptors (PPAR-γ). Activation of receptor PPAR-γ regulates
carbohydrate and lipid metabolism, immune and inflammatory responses in heart tissues.
Our aim will to study the effect of pioglitazone on insulin resistance, the clinical course
of atherosclerosis and coronary heart disease (CHD).
The study will include 43 patients with coronary artery disease. Patients will be divided
into the study group - 20 patients, in whom pioglitazone will be included in the combined
therapy at a dose of 15 mg 1 time per day in the morning, and the control group - 23 patients
receiving standard complex drug therapy over 6 months. Patients will be underwent clinical
examination, ultrasound of neck vessels, study of carbohydrate and lipid metabolism.
The end primary points of the study will be the onset of death due to myocardial infarction,
coronary revascularization procedures (coronary artery bypass grafting (CABG) or percutaneous
coronary intervention (PCI)), or hospitalization for acute coronary syndrome (ACS) or
unstable angina (UA).
Predefined secondary end points included carotic atherosclerotic leisure (carotic
intima-media thickness, diameter of stenosis, presents of atherosclerotic plaque), systemic
inflammation level (the level of C reactive protein), lipid metabolism (levels of serum total
cholesterol, triglycerides, high and low density lipoproteins), level of insulin resistance (
oral glucose tolerance test, blood glucose).